AURO LABORATORIES
|
AURO LABORATORIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| CEPS(Rs) | 4.71 | 14.26 | 5.64 | 6.20 | 13.18 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 68.94 | 67.32 | 54.87 | 50.58 | 45.86 |
| Tax Rate(%) | 2.24 | 24.68 | 29.13 | 26.57 | 31.66 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.55 | 19.89 | 8.30 | 9.09 | 20.72 |
| EBIT Margin(%) | 15.28 | 20.66 | 8.05 | 9.24 | 20.21 |
| Pre Tax Margin(%) | 9.70 | 19.29 | 6.51 | 7.62 | 19.36 |
| PAT Margin (%) | 9.48 | 14.53 | 4.62 | 5.59 | 13.23 |
| Cash Profit Margin (%) | 15.13 | 16.56 | 6.65 | 7.59 | 15.14 |
| Performance Ratios | |||||
| ROA(%) | 1.99 | 11.00 | 4.40 | 5.87 | 19.34 |
| ROE(%) | 4.33 | 20.46 | 7.43 | 9.47 | 28.67 |
| ROCE(%) | 3.79 | 20.37 | 9.92 | 12.20 | 38.88 |
| Asset Turnover(x) | 0.21 | 0.76 | 0.95 | 1.05 | 1.46 |
| Sales/Fixed Asset(x) | 0.54 | 1.74 | 2.08 | 2.05 | 2.25 |
| Working Capital/Sales(x) | -151.79 | 7.75 | 3.02 | 2.95 | 2.90 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.86 | 0.57 | 0.48 | 0.49 | 0.44 |
| Receivable days | 214.37 | 87.78 | 89.77 | 75.03 | 44.00 |
| Inventory Days | 112.03 | 68.04 | 55.24 | 24.40 | 22.23 |
| Payable days | 246.16 | 121.53 | 83.56 | 59.08 | 67.05 |
| Valuation Parameters | |||||
| PER(x) | 78.15 | 12.89 | 13.95 | 21.98 | 7.04 |
| PCE(x) | 48.96 | 11.30 | 9.68 | 16.19 | 6.15 |
| Price/Book(x) | 3.34 | 2.39 | 1.00 | 1.98 | 1.77 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 9.70 | 2.33 | 0.72 | 1.26 | 0.72 |
| EV/Core EBITDA(x) | 46.33 | 10.27 | 7.13 | 11.18 | 3.26 |
| EV/EBIT(x) | 63.47 | 11.28 | 8.93 | 13.59 | 3.57 |
| EV/CE(x) | 2.14 | 1.83 | 0.94 | 1.16 | 0.93 |
| M Cap / Sales | 7.41 | 1.87 | 0.64 | 1.23 | 0.93 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -63.83 | 1.40 | 3.99 | -6.24 | 23.89 |
| Core EBITDA Growth(%) | -66.65 | 128.22 | -6.71 | -52.35 | 65.67 |
| EBIT Growth(%) | -73.26 | 160.13 | -9.37 | -57.13 | 76.27 |
| PAT Growth(%) | -76.40 | 219.09 | -14.15 | -60.38 | 77.08 |
| EPS Growth(%) | -76.40 | 219.09 | -14.15 | -60.38 | 77.08 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.05 | 0.63 | 0.19 | 0.44 | 0.11 |
| Current Ratio(x) | 0.99 | 1.29 | 1.97 | 1.86 | 3.03 |
| Quick Ratio(x) | 0.82 | 0.94 | 1.32 | 1.64 | 2.75 |
| Interest Cover(x) | 2.74 | 15.06 | 5.23 | 5.69 | 23.92 |
| Total Debt/Mcap(x) | 0.31 | 0.26 | 0.19 | 0.22 | 0.06 |
Compare Financial Ratios of peers of AURO LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AURO LABORATORIES | ₹158.5 Cr | 13.1% | 14.9% | 23.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹427,034.0 Cr | 0.9% | 5.3% | 1.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹169,211.0 Cr | -2.3% | -3.3% | 12.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹124,875.0 Cr | -3.3% | 2.8% | 19.7% | Stock Analytics | |
| CIPLA | ₹122,082.0 Cr | -1.6% | -9.2% | 4.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,873.0 Cr | NA | -3.5% | 4.6% | Stock Analytics | |
AURO LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AURO LABORATORIES | 13.1% |
14.9% |
23.8% |
| SENSEX | 0.8% |
1% |
9.9% |
You may also like the below Video Courses
